Immunophenotypic Detection of Measurable Residual (Stem Cell) Disease Using LAIP Approach in Acute Myeloid Leukemia

Overview

Journal Curr Protoc Cytom

Publisher Wiley

Specialty Cell Biology

Date 2019 Nov 26

PMID 31763792

Citations 28

Authors

Wendelien Zeijlemaker

Angele Kelder

Jacqueline Cloos

Gerrit Jan Schuurhuis

Affiliations

Soon will be listed here.

Abstract

Half of the patients with acute myeloid leukemia (AML), who achieve complete remission after chemotherapy treatment, will ultimately experience a relapse. Measurable residual disease (MRD) is an important post-treatment risk factor in AML, because it gives additional information about the depth of the remission. Within MRD, the small population of leukemic stem cells (LSCs) is thought to be at the base of the actual relapse. In this protocol, the flow cytometric detection of MRD and LSCs herein is outlined. We give a detailed overview of the sampling procedures for optimal multiparameter flow cytometry assessment of both MRD and LSC, using leukemia associated immunophenotypes (LAIPs) and LSC markers. Moreover, an overview of the gating strategies to detect LAIPs and LSC markers is provided. This protocol serves as guidance for flow cytometric detection of measurable residual (stem cell) disease necessary for proper therapeutic decision making in AML patients. © 2019 The Authors. Basic Protocol 1: Immunophenotypic LAIP detection for measurable residual disease monitoring Basic Protocol 2: Immunophenotypic detection of CD34+CD38- leukemic stem cells.

Citing Articles

TIM-3 marks measurable residual leukemic stem cells responsible for relapse after allogeneic stem cell transplantation.

Sakoda T, Kikushige Y, Irifune H, Kawano G, Harada T, Semba Y Cancer Sci. 2024; 116(3):698-709.

PMID: 39726280 PMC: 11875787. DOI: 10.1111/cas.16431.

Computational assessment of measurable residual disease in acute myeloid leukemia using mixture models.

Mocking T, Kelder A, Reuvekamp T, Ngai L, Rutten P, Gradowska P Commun Med (Lond). 2024; 4(1):271.

PMID: 39702555 PMC: 11659572. DOI: 10.1038/s43856-024-00700-x.

Imaging Flow Cytometry and Convolutional Neural Network-Based Classification Enable Discrimination of Hematopoietic and Leukemic Stem Cells in Acute Myeloid Leukemia.

Hybel T, Jensen S, Rodrigues M, Hybel T, Pedersen M, Qvick S Int J Mol Sci. 2024; 25(12).

PMID: 38928171 PMC: 11203419. DOI: 10.3390/ijms25126465.

Phenotypic Analysis of Hematopoietic Stem and Progenitor Cell Populations in Acute Myeloid Leukemia Based on Spectral Flow Cytometry, a 20-Color Panel, and Unsupervised Learning Algorithms.

Matthes T Int J Mol Sci. 2024; 25(5).

PMID: 38474094 PMC: 10932439. DOI: 10.3390/ijms25052847.

Minimal Residual Disease in Acute Myeloid Leukemia: Old and New Concepts.

Chea M, Rigolot L, Canali A, Vergez F Int J Mol Sci. 2024; 25(4).

PMID: 38396825 PMC: 10889505. DOI: 10.3390/ijms25042150.

References

Zeijlemaker W, Kelder A, Cloos J, Schuurhuis G . Immunophenotypic Detection of Measurable Residual (Stem Cell) Disease Using LAIP Approach in Acute Myeloid Leukemia. Curr Protoc Cytom. 2019; 91(1):e66. PMC: 6856793. DOI: 10.1002/cpcy.66. View

Schuurhuis G, Meel M, Wouters F, Min L, Terwijn M, de Jonge N . Normal hematopoietic stem cells within the AML bone marrow have a distinct and higher ALDH activity level than co-existing leukemic stem cells. PLoS One. 2013; 8(11):e78897. PMC: 3823975. DOI: 10.1371/journal.pone.0078897. View

van Rhenen A, Feller N, Kelder A, Westra A, Rombouts E, Zweegman S . High stem cell frequency in acute myeloid leukemia at diagnosis predicts high minimal residual disease and poor survival. Clin Cancer Res. 2005; 11(18):6520-7. DOI: 10.1158/1078-0432.CCR-05-0468. View

Zeijlemaker W, Kelder A, Wouters R, Valk P, Witte B, Cloos J . Absence of leukaemic CD34 cells in acute myeloid leukaemia is of high prognostic value: a longstanding controversy deciphered. Br J Haematol. 2015; 171(2):227-238. DOI: 10.1111/bjh.13572. View

Cloos J, Harris J, Janssen J, Kelder A, Huang F, Sijm G . Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia. J Vis Exp. 2018; (133). PMC: 5931431. DOI: 10.3791/56386. View

Schuurhuis G, Ossenkoppele G, Kelder A, Cloos J . Measurable residual disease in acute myeloid leukemia using flow cytometry: approaches for harmonization/standardization. Expert Rev Hematol. 2018; 11(12):921-935. DOI: 10.1080/17474086.2018.1549479. View

Becker M, Jordan C . Leukemia stem cells in 2010: current understanding and future directions. Blood Rev. 2011; 25(2):75-81. DOI: 10.1016/j.blre.2010.11.001. View

Ishikawa F, Yoshida S, Saito Y, Hijikata A, Kitamura H, Tanaka S . Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region. Nat Biotechnol. 2007; 25(11):1315-21. DOI: 10.1038/nbt1350. View

Zeijlemaker W, Kelder A, Oussoren-Brockhoff Y, Scholten W, Snel A, Veldhuizen D . Peripheral blood minimal residual disease may replace bone marrow minimal residual disease as an immunophenotypic biomarker for impending relapse in acute myeloid leukemia. Leukemia. 2015; 30(3):708-15. DOI: 10.1038/leu.2015.255. View

10.

Quek L, Otto G, Garnett C, Lhermitte L, Karamitros D, Stoilova B . Genetically distinct leukemic stem cells in human CD34- acute myeloid leukemia are arrested at a hemopoietic precursor-like stage. J Exp Med. 2016; 213(8):1513-35. PMC: 4986529. DOI: 10.1084/jem.20151775. View

11.

Zeijlemaker W, Kelder A, Oussoren-Brockhoff Y, Scholten W, Snel A, Veldhuizen D . A simple one-tube assay for immunophenotypical quantification of leukemic stem cells in acute myeloid leukemia. Leukemia. 2015; 30(2):439-46. DOI: 10.1038/leu.2015.252. View

12.

Hanekamp D, Cloos J, Schuurhuis G . Leukemic stem cells: identification and clinical application. Int J Hematol. 2017; 105(5):549-557. DOI: 10.1007/s12185-017-2221-5. View

13.

Hourigan C, Gale R, Gormley N, Ossenkoppele G, Walter R . Measurable residual disease testing in acute myeloid leukaemia. Leukemia. 2017; 31(7):1482-1490. DOI: 10.1038/leu.2017.113. View

14.

Kersten B, Valkering M, Wouters R, van Amerongen R, Hanekamp D, Kwidama Z . CD45RA, a specific marker for leukaemia stem cell sub-populations in acute myeloid leukaemia. Br J Haematol. 2016; 173(2):219-35. DOI: 10.1111/bjh.13941. View

15.

Blair A, Hogge D, Sutherland H . Most acute myeloid leukemia progenitor cells with long-term proliferative ability in vitro and in vivo have the phenotype CD34(+)/CD71(-)/HLA-DR-. Blood. 1998; 92(11):4325-35. View

16.

Jongen-Lavrencic M, Grob T, Hanekamp D, Kavelaars F, Al Hinai A, Zeilemaker A . Molecular Minimal Residual Disease in Acute Myeloid Leukemia. N Engl J Med. 2018; 378(13):1189-1199. DOI: 10.1056/NEJMoa1716863. View

17.

Terwijn M, Kelder A, Snel A, Rutten A, Scholten W, Oussoren Y . Minimal residual disease detection defined as the malignant fraction of the total primitive stem cell compartment offers additional prognostic information in acute myeloid leukaemia. Int J Lab Hematol. 2012; 34(4):432-41. DOI: 10.1111/j.1751-553X.2012.01416.x. View

18.

Ivey A, Hills R, Simpson M, Jovanovic J, Gilkes A, Grech A . Assessment of Minimal Residual Disease in Standard-Risk AML. N Engl J Med. 2016; 374(5):422-33. DOI: 10.1056/NEJMoa1507471. View

19.

Guenot C, Lacombe F, Allou K, Dumezy F, Feuillard J, Genevieve F . Peripheral blood minimal/measurable residual disease assessed in flow cytometry in acute myeloblastic leukemia. Leukemia. 2019; 33(7):1814-1816. DOI: 10.1038/s41375-019-0393-0. View

20.

Bonnet D, Dick J . Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med. 1997; 3(7):730-7. DOI: 10.1038/nm0797-730. View